Latest Regulatory News

IperionX has secured its first U.S. Army task order worth $1.3 million under a $99 million SBIR Phase III contract, marking a significant step in reshoring titanium production for U.S. defense needs.

OD6 Metals has secured a second regulatory approval to extend its Phase 2 drilling at the historic Gulf Creek Copper Project, targeting promising repeat mineral structures and deepening exploration near recent high-grade intercepts.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

European Lithium Ltd has released assay results from deep diamond drilling at Greenland’s Tanbreez Project, revealing high-grade rare earth mineralisation below the current resource estimate and setting the stage for resource expansion.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

IDM International shareholders have overwhelmingly approved Blackstone Minerals’ acquisition via a scheme of arrangement, setting the stage for a transformative merger in the copper-gold mining sector.

Kore Potash has signed non-binding term sheets with OWI-RAMS for a $2.2 billion funding package to develop its flagship Kola Potash Project in the Republic of Congo, combining senior secured finance and royalty-based funding under Shariah principles.

Finder Energy has spotlighted its Kuda Tasi and Jahal oil development opportunity at the APAC Energy Capital Assembly, revealing a robust resource base and a streamlined development strategy promising rapid returns.

VanEck Investments Limited has released a replacement Product Disclosure Statement for its VanEck Bentham Global Capital Securities Active ETF (ASX, GCAP), outlining an actively managed strategy focused on global subordinated debt securities with income and diversification benefits.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Torque Metals has completed its acquisition of Aston Minerals through a court-approved scheme of arrangement, issuing new shares to Aston securityholders and delisting Aston from the ASX. The combined entity will operate under Torque’s leadership with a refreshed board.

Hanwha Group claims US approval to fully own Austal, but independent checks suggest a narrower green light. Australian regulators still hold the final say on foreign ownership.